source
- Roivant's autoimmune drug brepocitinib succeeds in two pivotal trials, paving way for 2027 filingRoivant Sciences said its autoimmune drug brepocitinib met primary goals in two pivotal studies. The trials, which evaluated the drug in separate autoimmune indications, showed statistically signi…
- Astellas partners with AI Proteins on $400M computational drug discovery dealAstellas Pharma of Japan has entered a partnership with Boston based AI Proteins to apply its computational design platform to drug discovery. AI Proteins builds miniproteins from scratch using ar…